Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright

Verastem executives outlined the company’s commercial and clinical priorities at an H.C. Wainwright event, highlighting the launch of its AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated low-grade serous ovarian cancer and the advancement of its KRAS G12D inhibitor, VS-7375, across pancreatic, lung and colorectal cancers.

Nate Sanburn, Verastem’s chief business officer, said the company is pursuing two platforms: the commercial-stage combination of avutametnib and defactinib, marketed as the AVMAPKI FAKZYNJA CO-PACK, and VS-7375, its development-stage KRAS G12D program. The CO-PACK has received accelerated approval for KRAS-mutated low-grade serous ovarian cancer, while VS-7375 is being evaluated in Phase II studies in pancreatic cancer, non-small cell lung cancer and colorectal cancer.

Verastem plans to move toward Phase III trials for VS-7375 in those three tumor types in the first half of 2027, according to Sanburn.

Sanburn said the company made changes in the first quarter involving personnel and commercial tactics that contributed to its second-quarter performance. He noted that the launch experienced seasonality in the first quarter, which he said is expected in the disease setting, and that Verastem intends to continue refining its commercial approach through the end of 2026. The company’s prescribing base has been split roughly 60% academic centers and 40% community practices, Sanburn said. Verastem is seeking to further expand engagement with community-based gynecologic oncologists and medical oncologists, with an emphasis on both new patient starts and keeping patients on treatment.

Jon Pachter, Verastem’s chief scientific officer, said patients with KRAS-mutated low-grade serous ovarian cancer in the Phase II RAMP 201 trial remained on therapy for an average of 18 months. He said that, as is common in a new oncology launch, some initial patients were relatively sicker, and the company is working to reach patients earlier in their treatment journey, including around first recurrence.

Verastem’s confirmatory Phase III RAMP 301 study is fully enrolled and is expected to read out next year, Sanburn said. The trial is designed to confirm results in the KRAS-mutated population and may provide an opportunity to expand into KRAS wild-type disease. Sanburn said the company estimates that approximately 30% of the low-grade serous ovarian cancer market is KRAS-mutated and 70% is KRAS wild type. The company also expects to present analyses from RAMP 201 and an external-control comparison involving the GOG-0281 study at the upcoming International Gynecologic Cancer Society Congress.